Clinical Trial

Perceptive eClinical Launches ClinPhone 5: A Ground-breaking new RTSM Platform Delivering a Leap in Clinical Development Technology

Platform developed in collaboration with CRScube, capitalizing on learnings from world-leading pharma and biotech companies NOTTINGHAM, England, Nov. 11, 2024 /PRNewswire/…

2 months ago

Avirmax Inc. to Present at the ARVO Frontiers in Ocular Gene Therapy Research Conference

HAYWARD, Calif., Nov. 11, 2024 /PRNewswire/ -- Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will chair the…

2 months ago

HoneyNaps AI Diagnostic Medical Software as Featured in International Journal “Digital Health”

- Published clinical study on sleep apnea patients in the prestigious journal Digital Health - Clinical research on HoneyNaps SOMNUM…

2 months ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients…

2 months ago

CardioComm Solutions Integrates ECG Technology into Sony’s mSafety Platform

Collaboration Brings Advanced ECG Monitoring to Sony's Wearable Health SolutionToronto, Ontario--(Newsfile Corp. - November 11, 2024) - CardioComm Solutions, (TSXV:…

2 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of…

2 months ago

Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company…

2 months ago

Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated…

2 months ago

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of…

2 months ago

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder…

2 months ago